Open an account

vTv Therapeutics

VTVT · NASDAQ

$27.85+$0.905 (+3.36%)TodayMarket closed ·
Prev close $26.94

About VTVT

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The company is headquartered in High Point, North Carolina and currently employs 26 full-time employees. The company went IPO on 2015-07-30. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

Employees
26
Headquarters
High Point, North Carolina
Listed
Jul 30, 2015
Sector
Health Care
Industry
Biotechnology
Website
vtvtherapeutics.com

VTVT key statistics

Market cap
104.94M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
26.26K
Volume
21.21K
Open price
$27.47
High today
$28.56
Low today
$27.07
52 Week high
$44.00
52 Week low
$19.50

vTv Therapeutics (VTVT) at a glance

As of Oct 20, 2026, vTv Therapeutics (VTVT) shares are priced at $27.85, giving the company a market cap of 104.94M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $27.07 and $28.56. The current price is 2.9% above the day's low and 2.5% below its high.

Volume so far is 21.21K shares, in line with the average of 26.26K shares a day.

Over the past year vTv Therapeutics has ranged from $19.50 to $44.00, and now sits 34% of the way up that range.

vTv Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$1.05 per share against an estimate of -$1.01.

The average analyst price target is $56.92, 104.4% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $56.92
Low
$42.42
Now
$27.85
High
$70.35

VTVT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 474.0% on average.

  1. Q1 FY24: reported -$1.17 per share against an estimate of -$0.0816
  2. Q4 FY24: reported -$0.55 per share against an estimate of -$0.8874
  3. Q1 FY25: reported -$0.77 per share against an estimate of -$0.8313
  4. Q2 FY25: reported -$0.92 per share against an estimate of -$0.8415
  5. Q3 FY25: reported -$1.08 per share against an estimate of -$0.9996
  6. Q4 FY25: reported -$0.58 per share against an estimate of -$1.11
  7. Q1 FY26: reported $1.65 per share against an estimate of -$0.0969
  8. Q2 FY26: reported -$1.05 per share against an estimate of -$1.01

VTVT news

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Press releaseGlobe Newswire

    vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

  • Press releaseGlobe Newswire

    vTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releasePRNewswire

    CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCER

  • Avi Kapoor

    Dow Edges Lower; Ventyx Biosciences Shares Plummet

  • Avi Kapoor

    Why Bank of Marin Bancorp Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session

Similar companies

Companies in the same industry as vTv Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.